Primer | Published:

Fibromyalgia

Nature Reviews Disease Primers volume 1, Article number: 15022 (2015) | Download Citation

Abstract

Fibromyalgia is a common illness characterized by chronic widespread pain, sleep problems (including unrefreshing sleep), physical exhaustion and cognitive difficulties. The definition, pathogenesis and treatment are controversial, and some even contest the existence of this disorder. In 1990, the American College of Rheumatology (ACR) defined classification criteria that required multiple tender points (areas of tenderness occurring in muscles and muscle–tendon junctions) and chronic widespread pain. In 2010, the ACR preliminary diagnostic criteria excluded tender points, allowed less extensive pain and placed reliance on patient-reported somatic symptoms and cognitive difficulties. Fibromyalgia occurs in all populations worldwide, and symptom prevalence ranges between 2% and 4% in the general population. The prevalence of people who are actually diagnosed with fibromyalgia (‘administrative prevalence’) is much lower. A model of fibromyalgia pathogenesis has been suggested in which biological and psychosocial variables interact to influence the predisposition, triggering and aggravation of a chronic disease, but the details are unclear. Diagnosis requires the history of a typical cluster of symptoms and the exclusion of a somatic disease that sufficiently explains the symptoms by medical examination. Current evidence-based guidelines emphasize the value of multimodal treatments, which encompass both non-pharmacological and selected pharmacological treatments tailored to individual symptoms, including pain, fatigue, sleep problems and mood problems. For an illustrated summary of this Primer, visit: http://go.nature.com/LIBdDX

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Fibromyalgia wars. J. Rheumatol. 36, 671–678 (2009).

  2. 2.

    & Culture, science and the changing nature of fibromyalgia. Nat. Rev. Rheumatol. 9, 751–755 (2013). A detailed overview on the different definitions and understanding of fibromyalgia over the past 100 years.

  3. 3.

    et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 33, 160–172 (1990).

  4. 4.

    World Health Organization. International Classification of Diseases (ICD). WHO , (2015).

  5. 5.

    et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. (Hoboken) 62, 600–610 (2010). This paper reports the development of the 2010 ACR preliminary diagnostic criteria for fibromyalgia.

  6. 6.

    , , & [What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association]. Schmerz 22, 176–183 (in German) (2008).

  7. 7.

    , & Management of functional somatic syndromes. Lancet 369, 946–955 (2007).

  8. 8.

    , & Fibromyalgia and psychiatric disorders. Acta Biomed. 78, 88–95 (2007).

  9. 9.

    et al. Fibromyalgia and arthritides. Reumatismo 64, 286–292 (2012).

  10. 10.

    et al. [Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis]. Schmerz 26, 247–258 (in German) (2012).

  11. 11.

    et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual. Life Outcomes 9, 71 (2011).

  12. 12.

    , , & Patient Health Questionnaire 15 as a generic measure of severity in fibromyalgia syndrome: surveys with patients of three different settings. J. Psychosom. Res. 76, 307–311 (2014).

  13. 13.

    & Fibromyalgia: an unhelpful diagnosis for patients and doctors. BMJ 348, g2168 (2014).

  14. 14.

    & Fibromyalgia syndrome: a somatoform disorder? Eur. J. Pain 18, 1052–1059 (2014).

  15. 15.

    Practical and evidence-based approach to common symptoms: a narrative review. Ann. Intern. Med. 161, 579–586 (2014).

  16. 16.

    Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin. Arthritis Rheum. 37, 339–352 (2008).

  17. 17.

    Fibromyalgia: a clinical review. JAMA 311, 1547–1555 (2014). An up-to-date clinical review on fibromyalgia.

  18. 18.

    & Fibromyalgia from the perspective of neuropathic pain. J. Rheumatol. Suppl. 75, 1–5 (2005).

  19. 19.

    et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J. Rheumatol. 38, 1113–1122 (2011).

  20. 20.

    Worldwide epidemiology of fibromyalgia. Curr. Pain Headache Rep. 17, 356 (2013). A systematic review on population-based studies of the prevalence of fibromyalgia.

  21. 21.

    et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes. J. Clin. Rheumatol. 12, 124–128 (2006).

  22. 22.

    et al. An epidemiologic internet survey of fibromyalgia and chronic pain in Japan. Arthritis Care Res. (Hoboken) 66, 1093–1101 (2014).

  23. 23.

    et al. Construction of a US fibromyalgia registry using the Fibromyalgia Research Survey criteria. Clin. Transl. Sci. 6, 398–399 (2013).

  24. 24.

    et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res. (Hoboken) 65, 786–792 (2013).

  25. 25.

    , & [Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008–2009]. Schmerz 25, 402–404, 406–410 (in German) (2011).

  26. 26.

    et al. [Mental disorders in patients with fibromyalgia syndrome: screening in centres of different medical specialties]. Schmerz 27, 296–304 (in German) (2013).

  27. 27.

    , , , & An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet. Disord. 8, 27 (2007).

  28. 28.

    et al. The German fibromyalgia consumer reports — a cross-sectional survey. BMC Musculoskelet. Disord. 13, 74 (2012).

  29. 29.

    , , & Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res. (Hoboken) 65, 777–785 (2013). A survey of a sample representative of the general population on fibromyalgia symptoms.

  30. 30.

    , , , & The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 38, 19–28 (1995).

  31. 31.

    et al. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 67, 568–575 (2015).

  32. 32.

    , , & The phenotypic and genetic signatures of common musculoskeletal pain conditions. Nat. Rev. Rheumatol. 9, 340–350 (2013).

  33. 33.

    et al. Family study of fibromyalgia. Arthritis Rheum. 50, 944–952 (2004).

  34. 34.

    , , & Familial aggregation in the fibromyalgia syndrome. Semin. Arthritis Rheum. 26, 605–611 (1996).

  35. 35.

    , , & A population-based twin study of functional somatic syndromes. Psychol. Med. 39, 497–505 (2009).

  36. 36.

    et al. Clustering of symptoms associated with fibromyalgia in a Finnish twin cohort. Eur. J. Pain 13, 744–750 (2009).

  37. 37.

    , & Mechanisms of disease: genetics of fibromyalgia. Nat. Clin. Pract. Rheumatol. 2, 671–678 (2006).

  38. 38.

    et al. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis Rheum. 65, 1122–1128 (2013).

  39. 39.

    et al. Genome-wide analysis of single nucleotide polymorphisms and copy number variants in fibromyalgia suggest a role for the central nervous system. Pain 155, 1102–1109 (2014).

  40. 40.

    What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn. Mol. Psychiatry 18, 1058–1066 (2013).

  41. 41.

    et al. Finding the missing heritability of complex diseases. Nature 461, 747–753 (2009).

  42. 42.

    , & Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun. Rev. 8, 41–43 (2008).

  43. 43.

    , , , & Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum. 40, 446–452 (1997).

  44. 44.

    et al. [Etiology and pathophysiology of fibromyalgia syndrome]. Schmerz 26, 259–267 (in German) (2012).

  45. 45.

    et al. Fibromyalgia and physical trauma: the concepts we invent. J. Rheumatol. 41, 1737–1745 (2014).

  46. 46.

    et al. Frequency of axial spondyloarthropathy among patients suffering from fibromyalgia a magnetic resonance immaging study with application of the Assessment of Spondylo-Arthritis international Society classification criteria. Arthritis Rheum. Abstr. 65, 128 (2013).

  47. 47.

    , & The frequency of hypermobility and its relationship with clinical findings of fibromyalgia patients. Clin. Rheumatol. 26, 485–487 (2007).

  48. 48.

    , , , & Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care Res. (Hoboken) 63, 808–820 (2011).

  49. 49.

    et al. Work stress and incidence of newly diagnosed fibromyalgia: prospective cohort study. J. Psychosom. Res. 57, 417–422 (2004).

  50. 50.

    , , & Holocaust survivors: the pain behind the agony. Increased prevalence of fibromyalgia among Holocaust survivors. Clin. Exp. Rheumatol. 28, S51–S56 (2010).

  51. 51.

    et al. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin. Arthritis Rheum. 29, 217–227 (2000).

  52. 52.

    et al. Heart rate variability in patients with fibromyalgia and patients with chronic fatigue syndrome: a systematic review. Semin. Arthritis Rheum. 43, 279–287 (2013).

  53. 53.

    & Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum. 65, 291–302 (2013). An excellent overview on the importance of central pain mechanisms in rheumatic diseases.

  54. 54.

    , , , & Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 64, 2907–2916 (2012).

  55. 55.

    et al. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. Arthritis Rheumatol. 67, 1386–1394 (2015).

  56. 56.

    , , & Primary total knee arthroplasty in patients with fibromyalgia. Orthopedics 35, e175–e178 (2012).

  57. 57.

    Central sensitization: implications for the diagnosis and treatment of pain. Pain 152, S2–S15 (2011).

  58. 58.

    , & Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J. Pain 8, 893–901 (2007).

  59. 59.

    , , , & Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91, 165–175 (2001).

  60. 60.

    , , , & Temporal summation of pain is not amplified in a large proportion of fibromyalgia patients. Pain Res. Treat. 2012, 938595 (2012).

  61. 61.

    , , & Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114, 295–302 (2005).

  62. 62.

    , , & Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain 145, 18–23 (2009).

  63. 63.

    , , & Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 35, 550–556 (1992).

  64. 64.

    , & Pathogenesis of fibromyalgia — a review. Joint Bone Spine 75, 273–279 (2008).

  65. 65.

    , , , & Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst. Rev. 1, CD010292 (2013).

  66. 66.

    , , , & Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153, 1193–1198 (2012).

  67. 67.

    et al. Decreased central μ-opioid receptor availability in fibromyalgia. J. Neurosci. 27, 10000–10006 (2007).

  68. 68.

    , & No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7. Pain 46, 139–143 (1991).

  69. 69.

    , , & The “Toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol. Sci. 30, 581–591 (2009).

  70. 70.

    & Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 10, 663–672 (2009).

  71. 71.

    , , & Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr. Pain Headache Rep. 11, 343–351 (2007).

  72. 72.

    et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum. 60, 3146–3152 (2009).

  73. 73.

    et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology 119, 1453–1464 (2013).

  74. 74.

    et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. Pain 155, 2517–2525 (2014).

  75. 75.

    , & Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J. Rheumatol. 26, 1564–1569 (1999).

  76. 76.

    et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 37, 1593–1601 (1994).

  77. 77.

    , , & Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 46, 1333–1343 (2002).

  78. 78.

    et al. Functional imaging of pain in patients with primary fibromyalgia. J. Rheumatol. 31, 364–378 (2004).

  79. 79.

    et al. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum. 62, 2545–2555 (2010).

  80. 80.

    , , & Decreased intrinsic brain connectivity is associated with reduced clinical pain in fibromyalgia. Arthritis Rheum. 64, 2398–2403 (2012).

  81. 81.

    et al. Patients with fibromyalgia display less functional connectivity in the brain's pain inhibitory network. Mol. Pain 8, 32 (2012).

  82. 82.

    et al. Reduced insular γ-aminobutyric acid in fibromyalgia. Arthritis Rheum. 64, 579–583 (2012).

  83. 83.

    et al. Association between alcohol consumption and symptom severity and quality of life in patients with fibromyalgia. Arthritis Res. Ther. 15, R42 (2013).

  84. 84.

    & Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10, 23–36 (2009).

  85. 85.

    , & Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet. Disord. 12, 245 (2011).

  86. 86.

    et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain 136, 1857–1867 (2013).

  87. 87.

    , & The science of fibromyalgia. Mayo Clin. Proc. 86, 907–911 (2011).

  88. 88.

    , , , & Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case–control studies. J. Clin. Rheumatol. 20, 146–150 (2014).

  89. 89.

    , & An evolutionary stress-response hypothesis for chronic widespread pain (fibromyalgia syndrome). Pain Med. 12, 1167–1178 (2011).

  90. 90.

    & Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. Prog. Mol. Biol. Transl. Sci. 131, 409–434 (2015).

  91. 91.

    & Key mechanisms mediating fibromyalgia. Clin. Exp. Rheumatol 33, S3–S6 (2015).

  92. 92.

    et al. Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. Evid. Based Complement. Alternat. Med. 2013, 528952 (2013). A systematic review on the recommendations of recent evidence-based interdisciplinary guidelines for the clinical diagnosis of fibromyalgia.

  93. 93.

    & Two contributions to understanding of the ‘fibrositis’ syndrome. Bull. Rheum. Dis. 28, 928–931 (1977–1978).

  94. 94.

    Primary fibromyalgia syndrome: a critical evaluation of recent criteria developments. Z. Rheumatol. 48 217–222 (1989).

  95. 95.

    & Fibromyalgia diagnosis and diagnostic criteria. Ann. Med. 495–502 (2011).

  96. 96.

    Stop using the American College of Rheumatology criteria in the clinic. J. Rheumatol. 30, 1671–1672 (2003).

  97. 97.

    , , , & A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J. Rheumatol. 24, 377–383 (1997).

  98. 98.

    , , , & What do tender points measure? Influence of distress on 4 measures of tenderness. J. Rheumatol. 30, 567–574 (2003).

  99. 99.

    A pain psychologist's view of tenderness in fibromyalgia. J. Rheumatol. 34, 912–913 (2007).

  100. 100.

    Editorial: the status of fibromyalgia criteria. Arthritis Rheumatol. 67, 330–333 (2015).

  101. 101.

    et al. The 2010 American College of Rheumatology Fibromyalgia Survey diagnostic criteria and Symptom Severity Scale is a valid and reliable tool in a French speaking fibromyalgia cohort. BMC Musculoskelet. Disord. 13, 179 (2012).

  102. 102.

    et al. Validation of the Fibromyalgia Survey Questionnaire within a cross-sectional survey. PLoS ONE 7, e37504 (2012).

  103. 103.

    et al. The Japanese version of the modified ACR preliminary diagnostic criteria for fibromyalgia and the Fibromyalgia Symptom Scale: reliability and validity. Mod. Rheumatol. 23, 846–850 (2013).

  104. 104.

    et al. Validation of the modified 2010 American College of Rheumatology diagnostic criteria for fibromyalgia in a Spanish population. Rheumatology (Oxford) 53, 1803–1811 (2014).

  105. 105.

    et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv. Res. 10, 102 (2010).

  106. 106.

    & Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford) 42, 263–267 (2003).

  107. 107.

    et al. Misdiagnosis in fibromyalgia: a multicentre study. Clin. Exp. Rheumatol. 29, S104–S108 (2011).

  108. 108.

    et al. Most patients diagnosed with fibromyalgia by physicians do not have fibromyalgia: the 2012 National Health Interview Survey Fibromyalgia Study. (2015).

  109. 109.

    et al. Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability. Ann. Rheum. Dis. 61, 660–661 (2002).

  110. 110.

    , & Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care Res. (Hoboken) 62, 611–617 (2010).

  111. 111.

    , , , & The development of fibromyalgia — I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 152, 291–299 (2011).

  112. 112.

    , & The role of life stress in fibromyalgia. Curr. Rheumatol. Rep. 7, 365–370 (2005).

  113. 113.

    & Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis Rheum. 64, 281–284 (2012).

  114. 114.

    , , & Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res. Ther. 16, 201 (2014). A recent qualitative review on the potential and limitations of drug therapy in fibromyalgia.

  115. 115.

    , , , & Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann. Rheum. Dis. 72, 955–962 (2013).

  116. 116.

    & More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: a meta-analysis examining six core symptoms. Eur. J. Pain 18, 1067–1080 (2014). A recent systematic review with a meta-analysis of non-pharmacological and pharmacological treatments for fibromyalgia.

  117. 117.

    , , , & Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst. Rev. 9, CD009796 (2013).

  118. 118.

    et al. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain 155, 693–702 (2014).

  119. 119.

    , , , & A systematic review and meta-analysis of mindfulness-based stress reduction for the fibromyalgia syndrome. J. Psychosom. Res. 75, 500–510 (2013).

  120. 120.

    et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Res. Ther. 16, 451 (2014).

  121. 121.

    , , , & Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum. 61, 216–224 (2009).

  122. 122.

    , , , & Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials. Rheumatol. Int. 33, 193–207 (2013).

  123. 123.

    , , & The effectiveness of hydrotherapy in the management of fibromyalgia syndrome: a systematic review. Rheumatol. Int. 29, 119–130 (2008).

  124. 124.

    et al. [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. Schmerz 26, 297–310 (in German) (2012).

  125. 125.

    et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin. J. Pain 31, 7–13 (2015).

  126. 126.

    , , & Anticonvulsants for fibromyalgia. Cochrane Database Syst. Rev. 10, CD010782 (2013).

  127. 127.

    , , , & Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J. Rheumatol. 38, 2653–2663 (2011).

  128. 128.

    , , , & The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 26, 297–307 (2012).

  129. 129.

    , & New concepts in pain research and pain management of the rheumatic diseases. Semin. Arthritis Rheum. 41, 319–334 (2011).

  130. 130.

    , , & Nabilone for the treatment of pain in fibromyalgia. J. Pain 9, 164–173 (2008).

  131. 131.

    , , & The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth. Analg. 110, 604–610 (2010).

  132. 132.

    & A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 52, 2495–2505 (2005).

  133. 133.

    , , , & Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin. Rheumatol. 12, 186–191 (1993).

  134. 134.

    et al. Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology (Berl.). 231, 2525–2531 (2014).

  135. 135.

    et al. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur. J. Pain 15, 509–514 (2011).

  136. 136.

    , , & Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin. Exp. Rheumatol. 30, 78–87 (2012).

  137. 137.

    , & Monotherapy or combination therapy for fibromyalgia treatment? Curr. Rheumatol. Rep. 14, 568–575 (2012).

  138. 138.

    et al. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 149, 360–364 (2010).

  139. 139.

    et al. Characteristics of patients with fibromyalgia in France and Germany. Int. J. Clin. Pract. 64, 1100–1108 (2010).

  140. 140.

    , , & EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J. Rheumatol. 37, 296–304 (2010). A comparison of different HRQOL measures in rheumatic diseases.

  141. 141.

    , , & A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 13, 873–884 (2004).

  142. 142.

    et al. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J. Rheumatol. 38, 2238–2246 (2011).

  143. 143.

    et al. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur. J. Pain 17, 581–586 (2013).

  144. 144.

    , , & Mortality in fibromyalgia: a study of 8,186 patients over thirty-five years. Arthritis Care Res. (Hoboken) 63, 94–101 (2011).

  145. 145.

    et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res. Ther. 11, R120 (2009).

  146. 146.

    , , , & Mortality in a cohort of Danish patients with fibromyalgia: increased frequency of suicide. Arthritis Rheum. 62, 3101–3108 (2010).

  147. 147.

    , & Hospitalisation charges for fibromyalgia in the United States, 1999–2007. Clin. Exp. Rheumatol. 30, 129–135 (2012).

  148. 148.

    et al. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon. Outcomes Res. 5, 171–180 (2013). A transatlantic comparison of health resource use and costs associated with fibromyalgia.

  149. 149.

    , & Women with fibromyalgia: work and rehabilitation. Disabil. Rehabil. 27, 685–694 (2005).

  150. 150.

    et al. Fibromyalgia syndrome in chronic disabling occupational musculoskeletal disorders: prevalence, risk factors, and posttreatment outcomes. J. Occup. Environ. Med. 52, 1186–1191 (2010).

  151. 151.

    , , & Social security work disability and its predictors in patients with fibromyalgia. Arthritis Care Res. (Hoboken) 66, 1354–1363 (2014).

  152. 152.

    , , & A cluster within the continuum of biopsychosocial distress can be labeled “fibromyalgia syndrome”— evidence from a representative German population survey. J. Rheumatol. 36, 2806–2812 (2009).

  153. 153.

    National Institute of Mental Health. Research Domain Criteria (RDoC). NIMH , (2015).

  154. 154.

    Social Security Administration. Social Security Ruling SSR 12-2p; Titles II and XVI: evaluation of fibromyalgia. Federal Register , (2012).

  155. 155.

    , , & Prevalence, health care utilization, and costs of fibromyalgia, irritable bowel, and chronic fatigue syndromes in the military health system, 2006–2010. Mil. Med. 179, 1021–1029 (2014).

  156. 156.

    & Technological adjuncts to increase adherence to therapy: a review. Clin. Psychol. Rev. 31, 697–710 (2011).

  157. 157.

    et al. Grand challenges in global mental health. Nature 475, 27–30 (2011). The NIMH recently launched the RDoC project. This ambitious project aims to create a framework for incorporating genetics, neuroscience and behavioural science findings into the research classification of mental disorders.

  158. 158.

    et al. Internet-enhanced management of fibromyalgia: a randomized controlled trial. Pain 151, 694–702 (2010).

  159. 159.

    et al. Virtual reality for persistent pain: a new direction for behavioral pain management. Pain 153, 2163–2166 (2012). An outlook on the potential of virtual reality for the psychological management of fibromyalgia.

  160. 160.

    , , & The molecular basis of pain and its implications in rheumatology. Nat. Clin. Pract. Rheumatol. 5, 28–37 (2009).

  161. 161.

    et al. [Fibromyalgia prevalence in Tunisia]. Tunis. Med. 86, 806–811 (in French) (2008).

  162. 162.

    et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J. Rheumatol. 31, 594–597 (2004).

  163. 163.

    , , & The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J. Rheumatol. 26, 1570–1576 (1999).

  164. 164.

    , & The epidemiology of self-reported fibromyalgia in Canada. Chron. Dis. Can. 27, 9–16 (2006).

  165. 165.

    et al. Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J. Rheumatol. 32, 348–353 (2005).

  166. 166.

    , & The prevalence of fibromyalgia syndrome in Chinese people in Hong Kong. J. Musculoskelet. Pain 14, 3–11 (2006).

  167. 167.

    et al. Prevalence of fibromyalgia in the Israeli population: a population-based study to estimate the prevalence of fibromyalgia in the Israeli population using the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ). Clin. Exp. Rheumatol. 30, 39–43 (2012).

  168. 168.

    , & Musculoskeletal pain in Malaysia: a COPCORD survey. J. Rheumatol. 34, 207–213 (2007).

  169. 169.

    & Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br. J. Rheumatol. 37, 491–495 (1998).

  170. 170.

    , & PSY5 estimating the prevalence of fibromyalgia and its impacts on health in Thais: a community-survey in Bangkok, Thailand. Value Health 15, A678 (2012).

  171. 171.

    et al. The epidemiological aspects of fibromyalgia syndrome in adults living in Turkey: a population based study. J. Musculoskelet. Pain 16, 141–147 (2008).

  172. 172.

    et al. Fibromyalgia in the adult Danish population: I. A prevalence study. Scand. J. Rheumatol. 22, 233–237 (1993).

  173. 173.

    et al. Fibromyalgia syndrome in the general population of France: a prevalence study. Joint Bone Spine 76, 184–187 (2009).

  174. 174.

    , , & Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: the DEFI study (Determination of Epidemiology of Fibromyalgia). BMC Musculoskelet. Disord. 12, 224 (2011).

  175. 175.

    & Prevalence of primary fibromyalgia in the Finnish population. BMJ 303, 216–219 (1991).

  176. 176.

    et al. Prevalence of fibromyalgia: a survey in five European countries. Semin. Arthritis Rheum. 39, 448–453 (2010).

  177. 177.

    et al. Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG study. J. Rheumatol. 30, 1589–1601 (2003).

  178. 178.

    , & Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin. Exp. Rheumatol. 23, 819–828 (2005).

  179. 179.

    , , & Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin. Exp. Rheumatol. 26, 519–526 (2008).

  180. 180.

    , , , & Prevalence of fibromyalgia and chronic widespread pain. Scand. J. Prim. Health Care 18, 149–153 (2000).

  181. 181.

    et al. Effect of fibromyalgia syndrome on the health-related quality of life and economic burden in Korea. Rheumatology (Oxford) 52, 311–320 (2013).

Download references

Acknowledgements

D. Clauw provided useful discussions and contributions to the writing and editing process but chose not to be credited with authorship. This manuscript was supported (in part) by the Intramural Research Program of the US NIH, National Center for Complementary and Integrative Health (NCCIH) and National Institute of Nursing Research (NINR). J.V.L. has a Miguel Servet research contract awarded by the Institute of Health Carlos III (CP14/00087; ISCIII, Madrid, Spain).

Author information

Affiliations

  1. Department of Internal Medicine 1, Klinikum Saarbrücken, Winterberg 1, D-66119 Saarbrücken, Germany.

    • Winfried Häuser
  2. Department Psychosomatic Medicine and Psychotherapy, Technische Universität München, Ismaninger Street 22, 81675 München, Germany.

    • Winfried Häuser
  3. Institute of Rheumatology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

    • Jacob Ablin
  4. McGill University Health Center, Montreal, Quebec, Canada.

    • Mary-Ann Fitzcharles
  5. Departments of Rheumatology and Medicine, Monash Health and Monash University, Clayton, Australia.

    • Geoffrey Littlejohn
  6. Teaching, Research and Innovation Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain.

    • Juan V. Luciano
  7. Department of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan.

    • Chie Usui
  8. National Center for Complementary and Integrative Health, and National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland, USA.

    • Brian Walitt

Authors

  1. Search for Winfried Häuser in:

  2. Search for Jacob Ablin in:

  3. Search for Mary-Ann Fitzcharles in:

  4. Search for Geoffrey Littlejohn in:

  5. Search for Juan V. Luciano in:

  6. Search for Chie Usui in:

  7. Search for Brian Walitt in:

Contributions

Introduction (W.H.); Epidemiology (W.H. and C.U.); Mechanisms/pathophysiology (J.A. and B.W.); Diagnosis, screening and prevention (G.L. and W.H); Management (M.-A.F. and J.V.L.); Quality of life (B.W. and G.L); Outlook (all authors); overview of Primer (W.H.).

Competing interests

B.W., J.V.L. and C.U. declare no competing interests. J.A. has received research funding and participated in educational activity sponsored by Pfizer. M.-A.F. has received consulting fees, speaking fees and/or honoraria from BioVale, Janssen, Eli Lilly, Pfizer, Purdue and Valeant. W.H. received one consulting fee from Daiichi Sankyo and honoraria for educational lectures by Abbott, MSD, Sharp & Dohme and Pfizer. G.L. has been involved in clinical trials for Pfizer and Eli Lilly at Monash Health and received consulting and/or speaking fees from Pfizer, Eli Lilly, Mundipharma, Grünenthal, bioCSL and Pierre Fabre Medicament Australia.

Corresponding author

Correspondence to Winfried Häuser.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrdp.2015.22

Further reading